These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 32853681)

  • 1. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
    Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
    Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
    Mosele MF; Westphalen CB; Stenzinger A; Barlesi F; Bayle A; Bièche I; Bonastre J; Castro E; Dienstmann R; Krämer A; Czarnecka AM; Meric-Bernstam F; Michiels S; Miller R; Normanno N; Reis-Filho J; Remon J; Robson M; Rouleau E; Scarpa A; Serrano C; Mateo J; André F
    Ann Oncol; 2024 Jul; 35(7):588-606. PubMed ID: 38834388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
    Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
    ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
    Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
    R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
    Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
    Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
    Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
    Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
    Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
    Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
    Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
    Zugazagoitia J; Rueda D; Carrizo N; Enguita AB; Gómez-Sánchez D; Díaz-Serrano A; Jiménez E; Mérida A; Calero R; Lujan R; De Miguel E; Gámez P; Díaz-Hellín V; Nuñez JA; Iglesias L; Ferrer I; Paz-Ares L; Ponce-Aix S
    Clin Lung Cancer; 2018 Jan; 19(1):65-73.e7. PubMed ID: 28780976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to read a next-generation sequencing report-what oncologists need to know.
    Schmid S; Jochum W; Padberg B; Demmer I; Mertz KD; Joerger M; Britschgi C; Matter MS; Rothschild SI; Omlin A
    ESMO Open; 2022 Oct; 7(5):100570. PubMed ID: 36183443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
    Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
    J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
    Suay G; Aparisi F; Juan-Vidal O
    Chin Clin Oncol; 2024 Jun; 13(3):46. PubMed ID: 38378474
    [No Abstract]   [Full Text] [Related]  

  • 19. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
    Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.